NT-proBNP provides incremental prognostic information in cardiac outpatients with and without echocardiographic findings
- PMID: 21400546
- PMCID: PMC6652603
- DOI: 10.1002/clc.20894
NT-proBNP provides incremental prognostic information in cardiac outpatients with and without echocardiographic findings
Abstract
Background: Outpatients frequently present with elevated natriuretic peptides in the absence of an obvious cardiac abnormality or with normal natriuretic peptides despite echocardiographic findings.
Hypothesis: We aimed to determine the prognostic value of N-terminal pro B-type natriuretic peptide (NTpBNP) in outpatients with normal and abnormal echocardiography.
Methods: A total of 433 cardiovascular outpatients were included. The prognostic value of NTpBNP in patients with normal and abnormal echocardiography during a 2-year follow-up was evaluated.
Results: Patients with abnormal echocardiography and elevated NTpBNP had a mortality rate of 8.7% and an overall event rate of 20.2% (composite end point of overall mortality, myocardial infarction, and hospitalization for heart failure), which was significantly higher than in patients with abnormal echocardiography and normal NTpBNP, in which no mortality (P=0.011) and no events were observed (P<0.001). In patients with a normal echocardiography, mortality was 1.5% and 1.8% for patients with normal and elevated NTpBNP, respectively (P=1.000). Composite event rate was 1.5% and 8.9% (P=0.093), respectively.
Conclusions: Patients with low NTpBNP have an excellent prognosis irrespective of echocardiographic findings. Therefore, determination of NTpBNP appears useful in assessing the clinical relevance of echocardiographic findings.
© 2011 Wiley Periodicals, Inc.
Figures

Similar articles
-
The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors.Intern Med. 2018 Sep 15;57(18):2621-2630. doi: 10.2169/internalmedicine.0471-17. Epub 2018 Apr 27. Intern Med. 2018. PMID: 29709934 Free PMC article.
-
Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy.Am J Cardiol. 2013 Oct 15;112(8):1190-6. doi: 10.1016/j.amjcard.2013.06.018. Epub 2013 Jul 19. Am J Cardiol. 2013. PMID: 23871673
-
Cardiac troponin T and N-terminal-pro-B type natriuretic peptide reflect myocardial function in preterm infants.J Perinatol. 2008 Jul;28(7):482-6. doi: 10.1038/jp.2008.21. Epub 2008 Mar 6. J Perinatol. 2008. PMID: 18322550
-
B-type natriuretic peptides and echocardiographic measures of cardiac structure and function.JACC Cardiovasc Imaging. 2009 Feb;2(2):216-25. doi: 10.1016/j.jcmg.2008.12.006. JACC Cardiovasc Imaging. 2009. PMID: 19356559 Review.
-
The predictive value of plasma biomarkers in discharged heart failure patients: role of plasma NT-proBNP.Minerva Cardioangiol. 2016 Apr;64(2):157-64. Epub 2015 Sep 15. Minerva Cardioangiol. 2016. PMID: 26373781 Review.
Cited by
-
The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study.BMC Cardiovasc Disord. 2021 Apr 21;21(1):202. doi: 10.1186/s12872-021-02010-9. BMC Cardiovasc Disord. 2021. PMID: 33882836 Free PMC article.
-
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.Clin Pharmacol Ther. 2021 Aug;110(2):498-507. doi: 10.1002/cpt.2222. Epub 2021 Mar 27. Clin Pharmacol Ther. 2021. PMID: 33630302 Free PMC article.
-
Serial measurements of N-terminal pro-brain natriuretic peptide in patients with coronary heart disease.PLoS One. 2015 Jan 28;10(1):e0117143. doi: 10.1371/journal.pone.0117143. eCollection 2015. PLoS One. 2015. PMID: 25629613 Free PMC article.
-
NT-proBNP is associated with mortality and adverse cardiac events in patients with atrial fibrillation presenting to the emergency department.Clin Cardiol. 2018 Mar;41(3):400-405. doi: 10.1002/clc.22883. Epub 2018 Feb 26. Clin Cardiol. 2018. PMID: 29480582 Free PMC article.
-
Mixed-methods evaluation of a multifaceted heart failure intervention in general practice: the OSCAR-HF pilot study.ESC Heart Fail. 2023 Apr;10(2):907-916. doi: 10.1002/ehf2.14251. Epub 2022 Dec 3. ESC Heart Fail. 2023. PMID: 36461750 Free PMC article.
References
-
- McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left‐ventricular systolic dysfunction. Lancet. 1998;351:9–13. - PubMed
-
- Mottram PM, Leano R, Marwick TH. Usefulness of B‐type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol. 2003;92:1434–1438. - PubMed
-
- Mueller C, Breithardt T, Laule‐Kilian K, et al. The integration of BNP and NT‐proBNP into clinical medicine. Swiss Med Wkly. 2007;137:4–12. - PubMed
-
- Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B‐type natriuretic peptide in comparison with those of A‐type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203. - PubMed
-
- Mueller C, Scholer A, Laule‐Kilian K, et al. Use of B‐type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647–654. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials